Trade Trade

Comment: Big Tech, Big Pharma and China face new scrutiny as EU recasts merger rules

By Nicholas Hirst
  • 03 May 2021 10:17
  • 04 May 2021 04:19
The EU's oversight of takeovers and acquisitions is undergoing its biggest revolution since the bloc's merger review was introduced in 1989.
A plethora of new initiatives at the national and EU level will see certain dealmakers — Big Tech, Big Pharma and Chinese buyers — navigating a maze of checks

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Nicholas Hirst

Chief Correspondent


Nicholas covers EU merger review and antitrust investigations for Mlex in Brussels. He previously wrote about EU affairs for Politico Europe, European Voice and PaRR. After earning an LLM in European law from the College of Europe in Bruges, he spent a year working in the competition practice of a leading competition law firm in Brussels 2009-10. He graduated in modern European languages from Oxford University in 2006.

Discover MLex

Stay on top of global regulatory developments

Latest News